Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Cardiovasc Toxicol ; 21(3): 192-205, 2021 03.
Article in English | MEDLINE | ID: mdl-33099748

ABSTRACT

High levels of serum uric acid is closely associated with atrial fibrillation (AF); nonetheless, the detailed mechanisms remain unknown. Therefore, this work examined the intricate mechanisms of AF triggered by hyperuricemia and the impact of the uricosuric agent benzbromarone on atrial remodeling in hyperuricemic rats. After adjusting baseline serum uric acid levels, a total of 28 healthy male adult Sprague Dawley rats were randomly divided into 4 groups, namely, control (CTR), hyperuricemia (oxonic acid potassium salt, OXO) and benzbromarone (+ BBR), and OXO withdrawal groups. Primary rat cardiomyocytes were cultured with uric acid for 24 h to investigate the direct influence of uric acid on cardiomyocytes. Results revealed that AF vulnerability and AF duration were dramatically greater in hyperuricemic rats (OXO group), while the atrial effective refractory periods (AERPs) were significantly shorter. Meanwhile, BBR treatment and withdrawal of 2% OXO administration remarkably reduced AF inducibility and shortened AF duration. Moreover, abnormal morphology of atrial myocytes, atrial fibrosis, apoptosis, and substantial sympathetic nerve sprouting were observed in hyperuricemic rats. Apoptosis and fibrosis of atria were partly mediated by caspase-3, BAX, TGF-ß1, and α-smooth muscle actin. Uric acid significantly induced primary rat cardiomyocyte apoptosis and fibrosis in vitro. Also, we found that sympathetic nerve sprouting was markedly upregulated in the atria of hyperuricemia rats, and was restored by BRB or absence of OXO administration. In summary, our study confirmed that AF induced by hyperuricemic rats occurred primarily via induction of atrial remodeling, thereby providing a novel potential treatment approach for hyperuricemia-related AF.


Subject(s)
Atrial Fibrillation/etiology , Atrial Remodeling , Heart Atria/metabolism , Hyperuricemia/complications , Myocytes, Cardiac/metabolism , Uric Acid/blood , Actins/metabolism , Animals , Apoptosis/drug effects , Atrial Fibrillation/metabolism , Atrial Fibrillation/physiopathology , Atrial Fibrillation/prevention & control , Atrial Remodeling/drug effects , Benzbromarone/pharmacology , Biomarkers/blood , Caspase 3/metabolism , Cells, Cultured , Disease Models, Animal , Fibrosis , Heart Atria/drug effects , Heart Atria/pathology , Heart Atria/physiopathology , Hyperuricemia/blood , Hyperuricemia/drug therapy , Male , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/pathology , Rats, Sprague-Dawley , Transforming Growth Factor beta1/metabolism , Uricosuric Agents/pharmacology , bcl-2-Associated X Protein/metabolism
2.
Clin Sci (Lond) ; 134(12): 1537-1553, 2020 06 26.
Article in English | MEDLINE | ID: mdl-32556103

ABSTRACT

Hyperuricaemia (HUA) significantly increases the risk of metabolic syndrome and is strongly associated with the increased prevalence of high serum free fatty acids (FFAs) and insulin resistance. However, the underlying mechanisms are not well established, especially the effect of uric acid (UA) on adipose tissue, a vital organ in regulating whole-body energy and FFA homeostasis. In the present study, we noticed that adipocytes from the white adipose tissue of patients with HUA were hypertrophied and had decreased UCP1 expression. To test the effects of UA on adipose tissue, we built both in vitro and in vivo HUA models and elucidated that a high level of UA could induce hypertrophy of adipocytes, inhibit their hyperplasia and reduce their beige-like characteristics. According to mRNA-sequencing analysis, UA significantly decreased the expression of leptin in adipocytes, which was closely related to fatty acid metabolism and the AMPK signalling pathway, as indicated by KEGG pathway analysis. Moreover, lowering UA using benzbromarone (a uricosuric agent) or metformin-induced activation of AMPK expression significantly attenuated UA-induced FFA metabolism impairment and adipose beiging suppression, which subsequently alleviated serum FFA elevation and insulin resistance in HUA mice. Taken together, these observations confirm that UA is involved in the aetiology of metabolic abnormalities in adipose tissue by regulating leptin-AMPK pathway, and metformin could lessen HUA-induced serum FFA elevation and insulin resistance by improving adipose tissue function via AMPK activation. Therefore, metformin could represent a novel treatment strategy for HUA-related metabolic disorders.


Subject(s)
Adipocytes/pathology , Adipose Tissue, Beige/pathology , Adipose Tissue, White/pathology , Fatty Acids, Nonesterified/blood , Hyperuricemia/blood , Hyperuricemia/drug therapy , Insulin Resistance , Metformin/therapeutic use , 3T3-L1 Cells , Adenylate Kinase/metabolism , Adipocytes/drug effects , Adipocytes/metabolism , Adipose Tissue, Beige/drug effects , Adipose Tissue, White/drug effects , Adult , Animals , Enzyme Activation , Female , Humans , Hypertrophy , Leptin/metabolism , Lipogenesis , Lipolysis , Male , Metformin/pharmacology , Mice , Mice, Inbred C57BL , Middle Aged , Signal Transduction , Triglycerides/metabolism , Uric Acid/blood
3.
Dermatol Ther ; 33(2): e13267, 2020 03.
Article in English | MEDLINE | ID: mdl-32052550

ABSTRACT

Lupus miliaris disseminates faciei (LMDF) is a rare inflammatory dermatosis characterized by an asymptomatic papular eruption in the central face, of which the etiology and pathogenesis are not clear. There is a lack of standard treatment recommendations, especially for severe cases. Here we report a new case of successful treatment of severe LMDF by the combination therapy of oral isotretinoin and methylprednisolone.


Subject(s)
Facial Dermatoses , Rosacea , Facial Dermatoses/drug therapy , Granuloma , Humans , Isotretinoin , Methylprednisolone
4.
J Am Heart Assoc ; 8(3): e011155, 2019 02 05.
Article in English | MEDLINE | ID: mdl-30686096

ABSTRACT

Background Whether chronic obstructive sleep apnea ( OSA ) could promote epicardial adipose tissue ( EAT ) secretion of profibrotic adipokines, and thereby contribute to atrial fibrosis, and the potential therapeutic effects of metoprolol remain unknown. Methods and Results A chronic OSA canine model was established by repeatedly clamping the endotracheal tube for and then reopening it for 4 hours every other day for 12 weeks. In a metoprolol treatment group, metoprolol succinate was administered daily for 12 weeks. The EAT infiltration and left atrial fibrosis were examined. The expressions of adipokines secreted by EAT and hypoxic 3T3-L1 adipocytes were detected. The changes in collagen synthesis, transforming growth factor-ß1 expression, and cell differentiation and proliferation in cardiac fibroblasts induced by hypoxic 3T3-L1 adipocyte-derived conditioned medium were further analyzed. Chronic OSA induced infiltration of EAT into the left atrium. OSA enhanced the profibrotic effect of EAT on the adjacent atrial myocardium. Moreover, OSA induced profibrotic cytokine secretion from EAT . We also found that hypoxia induced adipokine secretion in cultured adipocytes, and the medium conditioned by the hypoxic adipocytes increased collagen and transforming growth factor-ß1 protein expression and cell proliferation of cardiac fibroblasts. More importantly, metoprolol attenuated infiltration of EAT and alleviated the profibrotic effect of EAT by inhibiting adipokine secretion. Metoprolol also inhibited hypoxia-induced adipokine secretion in adipocytes and thereby blocked the hypoxic adipocyte-derived conditioned medium-induced fibrotic response of cardiac fibroblasts. Conclusions Chronic OSA enhanced the profibrotic effect of EAT on the neighboring atrial myocardium by stimulating the secretion of profibrotic adipokines from EAT , which was significantly attenuated by metoprolol. This study gives insights into mechanisms underlying OSA -induced atrial fibrillation and also provides experimental evidence for the protective effects of metoprolol.


Subject(s)
Adipose Tissue/pathology , Cardiomyopathies/prevention & control , Metoprolol/pharmacology , Pericardium/pathology , Sleep Apnea, Obstructive/drug therapy , Adipokines/metabolism , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Animals , Cardiomyopathies/diagnosis , Cardiomyopathies/etiology , Chronic Disease , Disease Models, Animal , Dogs , Fibrosis/diagnosis , Fibrosis/etiology , Fibrosis/prevention & control , Heart Atria/drug effects , Heart Atria/pathology , Male , Myocardium/pathology , Pericardium/drug effects , Pericardium/metabolism , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/diagnosis , Sympatholytics/pharmacology
5.
Platelets ; 30(6): 752-761, 2019.
Article in English | MEDLINE | ID: mdl-30252571

ABSTRACT

We performed this study to observe the effects of different doses of ticagrelor and standard-dose clopidogrel on platelet reactivity and endothelial function in diabetic patients with stable coronary artery disease (CAD). Sixty type 2 diabetic patients were assigned to one-quarter standard-dose ticagrelor, half standard-dose ticagrelor, standard-dose ticagrelor and standard-dose clopidogrel groups. Light transmission aggregometry (LTA) and VerifyNow assay were used to measure platelet function. Endothelial function was assessed by measurement of flow-mediated vasodilation (FMD) and plasma von Willebrand factor (VWF) levels were detected. Enzyme-linked immunosorbent assay (ELISA) examined the Interleukin-8(IL-8) and IL-10. The results suggested that the one-quarter dose (34.0%± 14.7%), half-dose (26.9%± 11.6%) and standard-dose (17.3%± 10.3%) ticagrelor showed lower platelet aggregation rate than clopidogrel (52.8%± 18.3%; P ï¼œ0.0001). PRU values in three ticagrelor groups were lower than that in clopidogrel group (102 (76-184);75 (33-88);38 (11-52) versus 194 (138-271) and;P ï¼œ0.0001). FMD levels were higher in ticagrelor groups compared with baseline levels while lower in clopidogrel group after treatment. However, no significant differences were found in the percentage increase in the FMD between ticagrelor groups and clopidogrel group. The levels of VWF after treatment were lower than the baseline levels, but there was no statistically significant difference between ticagrelor group and clopidogrel group after treatment. The concentration of IL-8 and IL-10 were decreased in patients with half and standard-dose ticagrelor group. In conclusion, one-quarter standard-dose ticagrelor produced similar inhibitory effects on platelet aggregation as standard-dose clopidogrel in diabetic patients with stable CAD. The half standard-dose ticagrelor had a similar inhibitory effect on platelet inhibition as standard-dose ticagrelor, which was stronger than that of clopidogrel. Moreover, the half-dose ticagrelor had equal protection of endothelial function and inhibition of inflammatory factor as standard-dose ticagrelor.


Subject(s)
Coronary Artery Disease/drug therapy , Diabetes Mellitus/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Platelet Aggregation/drug effects , Ticagrelor/therapeutic use , Adolescent , Adult , Aged , Coronary Artery Disease/pathology , Diabetes Mellitus/pathology , Female , Humans , Male , Middle Aged , Platelet Aggregation Inhibitors/pharmacology , Ticagrelor/pharmacology , Treatment Outcome , Young Adult
6.
J Am Heart Assoc ; 6(12)2017 12 21.
Article in English | MEDLINE | ID: mdl-29269354

ABSTRACT

BACKGROUND: The prevalence of atrial fibrillation (AF) is significantly higher in rheumatoid arthritis (RA) patients, but the underlying mechanisms remain poorly understood. The goal of this study was to assess the effects of RA on AF susceptibility and atrial arrhythmogenic remodeling in a rat model of RA. METHODS AND RESULTS: Collagen-induced arthritis was induced in rats by immunization with type II collagen in Freund's incomplete adjuvant. Among the rats that developed arthritis, AF susceptibility and atrial remodeling were examined 8 weeks after the primary immunization. AF inducibility and duration were substantially increased in collagen-induced arthritis rats, and AF duration was significantly and positively correlated with the serum IL-6 and TNF-α levels. Rats with collagen-induced arthritis showed prolonged atrial conduction time with no changes in the atrial effective refractory period. Atrial conduction delay was accompanied by significantly increased atrial fibrosis. In addition, atrial structural and autonomic remodeling, including left atrial dilation, apoptosis and autophagy of atrial myocytes, and atrial heterogeneous sympathetic hyperinnervation, was observed. Interestingly, we found that collagen-induced arthritis had no significant effects on connexins, Nav1.5, and the main ion channels' protein expressions in atria. CONCLUSIONS: We demonstrated that RA increased AF susceptibility by inducing AF-promoting atrial remodeling. This study may provide insights into mechanisms underlying RA-induced AF and validate a model that is suitable for further mechanistic and therapeutic exploration.


Subject(s)
Arthritis, Rheumatoid/complications , Atrial Fibrillation/etiology , Atrial Remodeling/physiology , Heart Conduction System/physiopathology , Animals , Arthritis, Rheumatoid/physiopathology , Atrial Fibrillation/physiopathology , Autonomic Nervous System/physiopathology , Disease Models, Animal , Female , Heart Rate , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL